Company Announcements: (reported by the Company) |
No items found
|
Elevator Pitch: | Currus Biologics is utilising its proprietary BEAT technology to develop CAR-T cell therapies for the treatment of solid tumour cancers, traditionally difficult to treat with current CAR-T cell therapies. Currus Biologics’ proprietary Bispecific Engagers of Antigen Presenting Cells and T cells (BEAT) technology overcomes many of the challenges presented when treating solid tumours with traditional CAR-T cell therapy, demonstrating CAR-T cell proliferation and persistence, CAR-T cell trafficking to the tumour and immunological memory extending to additional antigens. Currus Biologics is a privately held biotechnology company based in Melbourne, Australia. |
Category: | Health & biotech |
URL: | http://www.currusbio.com |
Operational Status: | Active |
ASX Listing Code (if applicable): | |
Year of Commencement: | 2021 |
Address: | 31 Queen St, Melbourne, Victoria 3000, AU |
State: | Victoria |
Overseas Operations: | No |
Twitter: | |
Facebook: | |
Linkedin: | https://www.linkedin.com/company/currus-biologics-pty-ltd/ |
Founders: | |
Awards won: | |